Rodon Biologics is a company with more than 20 years' experience in recombinant product production and process development. Rodon began operation in 1999 as Biotecnol, with services to support development of recombinant protein therapeutic products. In 2013 Rodon was created to focus on the services whilst Biotecnol continued as a customer of Rodon Biologics developing a multispecific antibody technology and immunocology products using this technology. In 2018 Rodon was acquired by a Portuguese Pharma CMO, Iberfar, becoming independent of Biotecnol.
Over the years Rodon have worked with clients from small start-ups through to larger pharma and biotech on an international level supporting projects from early research and discovery, through development and manufacture for clinical trials. Projects have been carried out using different expression systems for a range of recombinant product types including proteins such as mAbs, multispecifics, cytokine, growth factors, novel formats and small molecules such as polyamines. Rodon offer a ranges of services from DNA to drug product. We can engineer, produce and characterise from a few milligrams of to tens of grams of product for initial research, development and support continuing development with a stable cell line and robust scalable process and in partnership with CMOs GMP manufacture for clinical trials.
Our experience and track record make us the right partner to support the development of recombinant protein products. Rodon’s approach is customer centric establishing a close and flexible working relationship contributing positively to the success of our customer’s projects as we believe their success is our success.
Philip Cunnah Director of Services Know MorePhilip Cunnah Director of ServicesPhilip Cunnah, following a PhD at University College London, has over 20 years in the biotech industry with recombinant products. He has significant expertise at both the technical and commercial level having occupied a number of roles throughout his career from lab bench into senior management. He has taken products from gene through cell line, process, characterisation, preclinical development, scale-up and manufacture of finished goods for both industrial and pharmaceutical use. Currently he directs the services of Rodon Biologics supporting their customers Biologics programs.Follow Philip Cunnah on linkedin
Ana Rita Ricardo Director of Operations Know MoreAna Rita Ricardo Director of OperationsRita holds a Biotechnology Engineering Degree and a PhD degree in Biochemical Engineering from NOVA University of Lisbon. She has over 15 years of experience in the biopharmaceutical industry, managing projects for the development and expression of recombinant proteins. Her main expertise are in protein expression, DOE, upstream process development and cell-based assay development. At Rodon, Rita is also responsible for managing the operations and resources.Follow Ana Rita Ricardo on linkedin